StockNews.AI
ARDX
StockNews.AI
124 days

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

1. Ardelyx will hold a Q1 2025 conference call on May 1. 2. The company has two commercial products approved in the U.S. 3. Tenapanor has received regulatory approval in China and Japan. 4. The conference will provide business updates affecting its financial performance. 5. Ardelyx focuses on innovative medicines for significant unmet medical needs.

Earnings
+4.67%Current Return
VS
+0.14%S&P 500
$4.604/17 08:07 AM EDTEvent Start
$4.81504/18 02:33 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming conference indicating potential financial improvement and market communication, akin to past bullish responses after earnings calls.

How important is it?

The conference call may unveil key insights into Ardelyx's financial health and product performance which could shift investor perception.

Why Short Term?

Immediate details from the conference call could influence short-term investor sentiment, similar to prior earnings calls that had quick pricing responses.

Related Companies

KYKNYFOSUFKNTTF
Conference call scheduled for 4:30 p.m. Eastern Time April 17, 2025 08:00 ET  | Source: Ardelyx, Inc. WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 1, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2025. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call. About ArdelyxArdelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook. Investor and Media Contacts: Caitlin Lowieclowie@ardelyx.com

Related News